Search Results

You are looking at 41 - 47 of 47 items for :

  • "chemoprevention" x
  • Refine by Access: All x
Clear All
Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel

after RRSO, given the limitations inherent in nonrandomized studies. 175 , 176 Chemoprevention: Evaluation of the subset of healthy individuals with a BRCA1/2 mutation in the Breast Cancer Prevention Trial study showed that breast cancer risk was

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention . Curr Drug Targets 2011 ; 12 : 1909 – 1924 . 34. Dolinsky VW Rogan KJ Sung MM . Both aerobic exercise and resveratrol supplementation attenuate doxorubicin

Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass

smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial . Cancer Epidemiol Biomarkers Prev 2001 ; 10 : 823 – 829 . 70. Roach MC Rehman S

Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov

Byrne C . Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention . J Natl Cancer Inst 2001 ; 93 : 358 - 366 . 31 Spiegelman D Colditz GA Hunter D Hertzmark E . Validation of the Gail et

Full access

Peter G. Shields, Roy S. Herbst, Douglas Arenberg, Neal L. Benowitz, Laura Bierut, Julie Bylund Luckart, Paul Cinciripini, Bradley Collins, Sean David, James Davis, Brian Hitsman, Andrew Hyland, Margaret Lang, Scott Leischow, Elyse R. Park, W. Thomas Purcell, Jill Selzle, Andrea Silber, Sharon Spencer, Tawee Tanvetyanon, Brian Tiep, Hilary A. Tindle, Reginald Tucker-Seeley, James Urbanic, Monica Webb Hooper, Benny Weksler, C. Will Whitlock, Douglas E. Wood, Jennifer Burns, and Jillian Scavone

ES Lee JJ . The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial . Cancer Epidemiol Biomarkers Prev 2001 ; 10 : 823 – 829

Full access

ascertain their invasive risk characteristics. High-risk mTAs and sTAs could also be potential targets for chemoprevention and alternative future clinical management. Quality Improvement AB2017-61. Real-World Rates of Chemotherapy Use Near the End of

Full access

their primary clinician is unknown (although primary clinicians were notified of the recommendation for annual breast MRI). However, 15.7% (n=11) completed an MRI from this group, 32.4% (n=186) were eligible for chemoprevention, and 16.0% (n=86) were